Literature DB >> 31841164

Development of a Novel Orthotopic Primary Human Chordoma Xenograft Model: A Relevant Support for Future Research on Chordoma.

Henri Salle1,2,3,4, Marc Pocard1,2, Jacqueline Lehmann-Che5,6, Sylvie Bourthoumieu7, François Labrousse8, Cynthia Pimpie1, Leslie Lemnos4, Jean-Pierre Guichard9, Sebastien Froelich1, Homa Adle-Biassette10,11,12.   

Abstract

Chordomas are slow-growing rare malignant neoplasms. The aim of this study was to establish a primary model of chordoma in the lumbosacral orthotopic area, to compare the growth rate to the subcutaneous site, and to show that this new graft site optimizes tumor growth and bony invasion. Eleven chordoma samples were transplanted subcutaneously in the flank and/or in contact with the lumbosacral region and grown into nude mice. Engraftment rate was significantly more successful in the lumbosacral environment compared with the flank at P0. Two xenografts from 2 patients showed bone invasion. One tumor was maintained through multiple rounds of serial transplantation, creating a model for study. Histological and immunostaining analysis confirmed that tumor grafts recapitulated the primary tumor from which they were derived, consisting of a myxoid chordoma expressing brachyury, cytokeratin AE1, EMA, and VEGF. Clear destruction of the bone by the tumor cells could be demonstrated. Molecular studies revealed PIK3CA and PTEN mutations involved in PI3K signaling pathway and most of the frequently reported chromosomal alterations. We present a novel orthotopic primary xenograft model of chordoma implanted for the first time in the lumbosacral area showing bone invasion, PIK3CA, and PTEN mutations that will facilitate preclinical studies.
© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Chordoma; Orthotopic xenograft model; PIK3CA mutation; PTEN mutation; Patient derived xenograft (PDX)

Year:  2020        PMID: 31841164     DOI: 10.1093/jnen/nlz121

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  2 in total

1.  CORR Insights®: Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors.

Authors:  Lars Morawietz
Journal:  Clin Orthop Relat Res       Date:  2021-06-01       Impact factor: 4.755

2.  Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft.

Authors:  Thibault Passeri; Ahmed Dahmani; Julien Masliah-Planchon; Adnan Naguez; Marine Michou; Rania El Botty; Sophie Vacher; Rachida Bouarich; André Nicolas; Marc Polivka; Coralie Franck; Anne Schnitzler; Fariba Némati; Sergio Roman-Roman; Franck Bourdeaut; Homa Adle-Biassette; Hamid Mammar; Sébastien Froelich; Ivan Bièche; Didier Decaudin
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.